

HLA-DQB2 RABBIT PAB

Cat.#: S212973

Product Name: Anti-HLA-DQB2 Rabbit Polyclonal Antibody

Synonyms: DQB2; HLA-DXB; HLA-DQB1

UNIPROT ID: P05538 (Gene Accession - BC031995)

Background: HLA-DQB2 belongs to the family of HLA class II beta chain paralogs. Class II molecules are heterodimers consisting of an alpha (DQA) and a beta chain (DQB), both anchored in the membrane. They play a central role in the immune system by presenting peptides derived from extracellular proteins. Class II molecules are expressed in antigen presenting cells (APC: B lymphocytes, dendritic cells, macrophages). Polymorphisms in the alpha and beta chains specify the peptide binding specificity, and typing for these polymorphisms is routinely done for bone marrow transplantation. However this gene, HLA-DQB2, is not routinely typed, as it is not thought to have an effect on transplantation. There is conflicting evidence in the literature and public sequence databases for the protein-coding capacity of HLA-DQB2. Because there is evidence of transcription and an intact ORF, HLA-DQB2 is represented in Entrez Gene and in RefSeq as a protein-coding locus.

Immunogen: Fusion protein of human HLA-DQB2

Applications: ELISA, IHC

Recommended Dilutions: IHC: 50-200; ELISA: 5000-10000

Host Species: Rabbit

Clonality: Rabbit Polyclonal

Isotype: Immunogen-specific rabbit IgG


Purification: Antigen affinity purification

Species Reactivity: Human


Constituents: PBS (without Mg²⁺ and Ca²⁺), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

Research Areas: Immunology

Storage & Shipping: Store at -20°C. Avoid repeated freezing and thawing



Immunohistochemistry analysis of paraffin embedded Human liver cancer tissue using 212973 (HLA-DQB2 Antibody) at a dilution of 1/70 (Cytoplasm).



In comparison with the IHC on the left, the same paraffin-embedded Human liver cancer tissue is first treated with the fusion protein and then with 212973 (Anti-HLA-DQB2 Antibody) at dilution 1/70.



Product Description

Pioneering GTPase and Oncogene Product Development since 2010
